Since conventional therapeutic approaches in cancer are highly invasive they hardly prolong patient survival for more than few
months. Having the ability to stimulate both cellular and humoural immune responses, immunisation with naked plasmid DNA encoding
tumour-associated antigens or tumour-specific antigens has recently reported a plethora of advantages, and the improvement of vaccine
efficacy has emerged as a goal in the development of DNA vaccination as anti-tumour therapy.
Nevertheless, because of their poor immunogenicity when administered as unformulated intramuscular injections, plasmid DNA vaccines
need to be improved. Recent data suggest that the DNA vaccine efficacy may significantly be increased by electroporation. This review
highlights the recent literature that supports electroporation as an effective strategy to improve DNA-based vaccination protocols, investigating
the most relevant studies, recently developed for the applications of DNA vaccine electrotransfer against tumours in pre-clinical
and clinical studies.
Keywords: DNA vaccine, cancer, electroporation, immune response, tumour antigen, DNA Vaccination, Immunisation, Plasmid, Antigens, Skeletal Muscle, Melanoma, Viral vectors, Vector specific immunity
Rights & PermissionsPrintExport
Published on: 12 February, 2013
Page: [291 - 299]